Towards universal access: scaling up priority HIV/AIDS interventions in the health sector

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector Progress report 2009 Slide set – six summary data slides and all 40 figures from the report

Increase in antiretroviral therapy in low- and middle-income countries, adults and children [combined], December 2007–December 2008

Antiretroviral therapy coverage in low- and middle-income countries, adults and children [combined], December 2008

Antiretroviral therapy coverage in low- and middle-income countries, adults (≥15 years), December 2008

Antiretroviral therapy coverage in low- and middle-income countries, children (0–14 years), December 2008

Prevention of mother-to-child transmission coverage in low- and middle-income countries, December 2008

Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

Fig. 2.1. Transaction volumes of rapid HIV tests, 2004–2008

Fig. 2.2. Reported number of health facilities providing HIV testing and counselling services in low- and middle-income countries with comparable data, by region, 2007 and 2008

Fig. 2.3. Percentage of women with HIV testing and counselling and percentage of women with secondary or higher education, district comprehensive assessment districts in Burkina Faso, Haiti and Zambia, 2008

Fig. 2.4. Percentage of women and men receiving an HIV test and test results in the 12 months preceding the survey in countries with repeat population surveys, 2003–2008

Fig. 2.5. Percentage of women and men (≥15 years) who had ever received an HIV test and test results, South Africa, 2002, 2005 and 2008

Fig. 3.1. Situation analysis of harm reduction interventions in the Middle East and North Africa at baseline, 2008

Fig. 3.2. Blood donation per 1000 population, 2007

Fig. 4.1. Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

Fig. 4.2. Measuring attrition from antiretroviral therapy programmes

Fig. 4.3. Retention on antiretroviral therapy at 12 months after initiation of treatment in 61 low- and middle-income countries by region, 2008

Fig. 4.4. 12-month retention of people receiving antiretroviral therapy in selected treatment sites, Papua New Guinea, 2008

Fig. 4.5. Trends in retention on antiretroviral therapy in low- and middle-income countries by region, 2008

Fig. 4.6. Trends over time in the median CD4 count at baseline count of 36 715 adults starting antiretroviral therapy between 2001 and 2006

Fig. 4.7. Antiretroviral therapy coverage and all-cause mortality in South Africa, 2003–2006

Fig. 4.8. Countries implementing at least one element of the WHO Global Strategy for the Prevention and Assessment of HIV Drug Resistance and locations of HIV drug resistance testing laboratories, February 2009

Fig. 4.9. Main first-line antiretroviral regimens used among 2.4 million adults in 36 low- and middle-income countries, December 2008

Fig. 4.10. Main second-line antiretroviral regimens used among adults (n=51 135) in 36 low- and middle-income countries, December 2008

Fig. 4.11. First-line regimens used among children (n=177 064) in 36 low- and middle-income countries, December 2008

Fig. 4.12. Second-line regimens used among children (n=5997) in 35 low- and middle-income countries, December 2008

Fig. 4.13. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in low-income countries by year, 2004–2008

Fig. 4.14. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in lower-middle-income countries by year, 2004–2008

Fig. 4.15. Median price (in US dollars) of first-line antiretroviral drug regimens in upper-middle-income countries by year, 2004–2008

Fig. 4.16. Estimated HIV prevalence (%) among people newly infected with TB, 2007

Fig. 4.17. Rates of HIV testing among people with TB in countries in sub-Saharan Africa, 2004–2007

Fig. 5.1. Number of low- and middle-income countries with national scale-up plans including population-based targets for preventing mother-to-child transmission and for HIV care and treatment for children, by region, 2008

Fig. 5.2. Percentage of women and men aged 15–49 years with comprehensive knowledgea of HIV in countries with recent population-based surveys (2007–2008)

Fig. 5.3. Reported percentage condom use at last sexual intercourse among women 15–49 years old who had sex in the past year by five-year age groups in selected population-based surveys, 2005–2007

Fig. 5.4. Unmet need for family planning among married women 15–49 years old (%) in countries with a generalized epidemic, 2006–2008

Fig. 5.5. Percentage of pregnant women who received an HIV test in low- and middle-income countries by region, 2004–2008a

Fig. 5.6. Percentage of pregnant women who received an HIV test in Malawi, 2004–2008

Fig. 5.7. Percentage of pregnant women with HIV receiving antiretrovirals for preventing mother-to-child transmission of HIV in low- and middle-income countries by region, 2004–2008

Fig. 5.8. Percentage of pregnant women living with HIV who received antiretrovirals to prevent mother-to-child transmission of HIV in Côte d’Ivoire, 2005–2008

Fig. 5.9. Percentage of pregnant women living with HIV receiving antiretrovirals to prevent the mother-to-child transmission of HIV in 20 countries with the highest HIV disease burden among pregnant women (in descending order), 2008

Fig. 5.10. Coverage of antiretrovirals to prevent the mother-to-child transmission of HIV, 2008

Fig. 5.11. Percentage distribution of various antiretroviral regimens provided to pregnant women in low- and medium-income countries in 2007 and 2008, based on available data

Fig. 5.12. Contribution of the 20 countries with the largest numbers of women needing antiretrovirals for preventing the mother-to-child transmission of HIV to the global gap to reach 80% of those in need, 2008

Fig. 5.13. Coverage of antiretroviral prophylaxis among infants born to mothers living with HIV in low- and middle-income countries by region, 2008

Fig. 5.14. Percentage of pregnant women living with HIV and infants born to them who received antiretrovirals for preventing mother-to-child transmission, 2004–2008

Fig. 5.15. Average age of infants at their first HIV DNA test in Namibia in weeks, 2006–2008

Fig. 5.16. Percentage of children receiving antiretroviral therapy in low- and middle-income countries, 2005–2008

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector